The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Martins-Branco, Diogo; Kassapian, Marie; Debien, Véronique; Caparica, Rafael; Eiger, Daniel; Dafni, Urania; Andriakopoulou, Charitini; El-Abed, Sarra; Ellard, Susan L.; Izquierdo, Miguel; Vicente, Malou; Chumsri, Saranya; Piccart-Gebhart, Martine; Moreno-Aspitia, Alvaro; Knop, Ann Søegaard; Lombard, Janine; de Azambuja, Evandro

doi:10.1007/s10549-023-07159-9

Breast Cancer Res Treat

2023

DOI: 10.1007/s10549-023-07159-9

|View full text |Cite

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Diogo Martins-Branco,

Marie Kassapian,

Véronique Debien

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology

Vynnychenko,

Moskalenko

2024

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

In 2022, 2.3 million new cases of breast cancer were registered in the world, which accounted for 11.6% of the total number of malignant neoplasms. Depending on the tumor's molecular profile, the prognosis for patients can be different. One of the most aggressive types is HER2-positive breast cancer. Trastuzumab, a recombinant humanized monoclonal antibody against HER2, is used to treat such tumors. Congenital or acquired resistance to trastuzumab is one of the essential problems in clinical oncology. Our study aimed to investigate the resistance mechanisms to trastuzumab and ways to overcome them. This drug influences several directions of oncogenesis at the same time. The fundamental mechanisms of action of trastuzumab are inhibition of HER2 ectodomain shedding, inhibition of angiogenesis, degradation of HER2 protein and its internalization, inhibition of DNA repair, influence on the phosphatidylinositol 3-kinase pathway, cell cycle and antibody-dependent cellular cytotoxicity. The biological mechanisms of resistance to trastuzumab are based on vascular mimicry and hypoxia, the appearance of breast cancer stem cells, activation of alternative signaling pathways, metabolic changes, alternative molecular variants of HER2, changes in the processes of immune regulation, heterogeneity of expression and stability of the HER2 protein. In modern clinical oncology, trastuzumab is used as an original product and as antibody-drug conjugates. Trastuzumab emtansine and trastuzumab deruxtecan are approved for the treatment of patients with HER2-positive breast cancer, including those with low HER2 expression. This literature review identified the biological resistance mechanisms to trastuzumab and ways to overcome them. The implementation of new targeted drugs in combination with trastuzumab is the way to personalized treatment. It can significantly improve the survival of patients with HER2-positive breast cancer.

show abstract

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology

Vynnychenko,

Moskalenko

2024

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Cited by 1 publication

References 34 publications

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology

Contact Info

Product

Resources

About